Abiopharma

🔍 Saks Michael (Executive)

Company: RCM TECHNOLOGIES, INC. (RCMT)

Report Date: 2026-08-13

Detailed Transactions and Holdings:

• Acquired 4,000 shares of Common Stock (Direct)
  Date: 2026-08-13 | Code: A | equity_swap_involved: 0 | shares_owned_after: 108,195.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
• Acquired 2,904 shares of Common Stock (Direct)
  Date: 2026-08-13 | Code: A | equity_swap_involved: 0 | shares_owned_after: 111,099.00 | transaction_form_type: 4 | Footnotes: F4, F2
• Sold 6,792 shares of Common Stock at $32.5 per share (Direct)
  Date: 2026-08-14 | Code: S | equity_swap_involved: 0 | shares_owned_after: 104,307.00 | transaction_form_type: 4 | Footnotes: F5, F6
• Sold 5,000 shares of Common Stock at $35.0 per share (Direct)
  Date: 2026-08-14 | Code: S | equity_swap_involved: 0 | shares_owned_after: 99,307.00 | transaction_form_type: 4 | Footnotes: F5

Footnotes:

• F1: Represent time-based restricted stock units granted to the reporting person in August 2026 and reported in a Current Report on Form 8-K filed by the issuer in August 2026.
• F2: Received as employment compensation.
• F3: Includes 589 shares purchased pursuant to the Issuer's Employee Stock Purchase Plan since the reporting person's most recent filling under Section 16. Also, the amount shown in Table I, Column 5 as the "Amount of Securities Beneficially Owned Following Reported Transaction(s)" in the Reporting person's Form 4 filed on May 6, 2026 inadvertently omitted 14,339 shares relating to time-vested restricted stock units that were previously reported by the reporting person. Those 14,339 shares have been reflected here.
• F4: Represent shares acquired by the reporting person upon the vesting of performance stock units granted to the reporting person in May 2025 and previously reported in a Current Report on Form 8-K filed by the issuer in May 2025.
• F5: Represents a nondiscretionary sale by a plan established by the Reporting Person on December 6, 2024 in a manner intended to satisfy the requirements of Rule 10b5-1.
• F6: Represents the weighted average of a range of sale prices from $32.50 to $32.75. The reporting person undertakes to provide the Staff of Securities and Exchange Commission, the Company or any stockholder of the Company, upon request, full information regarding the number of shares sold at each separate price.